Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Halozyme Therapeutic (NQ: HALO ) 54.04 -0.26 (-0.48%) Streaming Delayed Price Updated: 12:14 PM EDT, Jul 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 156,666 Open 54.55 Bid (Size) 54.07 (1) Ask (Size) 54.11 (1) Prev. Close 54.30 Today's Range 53.74 - 54.59 52wk Range 32.83 - 55.82 Shares Outstanding 142,334,900 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News 3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition July 18, 2024 These biotech stocks have promising outlooks that will bring major fortune to investors. Buy before it is too late. Via InvestorPlace NASDAQ:HALO is showing good growth, while it is not too expensive. July 18, 2024 HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is not too expensive for the growth it is showing. Via Chartmill Performance YTD +44.53% +44.53% 1 Month +7.50% +7.50% 3 Month +42.93% +42.93% 6 Month +54.71% +54.71% 1 Year +28.70% +28.70% More News Read More Biotech Arvinas Stock Earns 82 RS Rating July 17, 2024 Via Investor's Business Daily Denali Therapeutics Stock Gets Technical Rating Upgrade July 16, 2024 Via Investor's Business Daily What 13 Analyst Ratings Have To Say About Halozyme Therapeutics July 16, 2024 Via Benzinga 3 Biotech Stocks to Buy Now: Q3 Edition July 15, 2024 Via InvestorPlace NASDAQ:HALO qualifies as a high growth stock and is consolidating. July 15, 2024 Via Chartmill NASDAQ:HALO Shows Potential for a Breakout. July 09, 2024 Via Chartmill Decoding 12 Analyst Evaluations For Halozyme Therapeutics June 24, 2024 Via Benzinga NASDAQ:HALO appears to be flying under the radar despite its strong fundamentals. July 12, 2024 Via Chartmill 3 Highly Rated Biotech Stocks for Your July Buy List July 05, 2024 Via InvestorPlace 3 Breakout Biotech Stocks on Track to Double by 2032 July 01, 2024 Via InvestorPlace UroGen Pharma Stock Earns 91 RS Rating June 27, 2024 Via Investor's Business Daily Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation. June 26, 2024 Via Chartmill Sarepta Therapeutics Scores 90-Plus RS Rating On Muscular Dystrophy Approval June 24, 2024 Via Investor's Business Daily NASDAQ:HALO: a strong growth stock preparing for the next leg up?. June 24, 2024 Via Chartmill Arcellx Stock Earns Relative Strength Rating Upgrade June 21, 2024 Via Investor's Business Daily Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87 June 20, 2024 Via Investor's Business Daily Don't overlook NASDAQ:HALO—it's a hidden gem with strong fundamentals and an attractive price tag. June 19, 2024 Via Chartmill The 3 Best Healthcare Stocks to Buy in June 2024 June 15, 2024 Via InvestorPlace Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans June 14, 2024 Via Investor's Business Daily Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade June 12, 2024 Via Investor's Business Daily Krystal Biotech Stock Sees RS Rating Jump To 91 June 11, 2024 Via Investor's Business Daily Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio? June 09, 2024 Via Benzinga Halozyme Therapeutics Scores RS Rating Jump To 91 June 07, 2024 Via Investor's Business Daily Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.